Review Article: Special Edition

**Lymphoid Tissue inducer (LTi) cell ontogeny and functioning in embryo and adult**

*Serge A. van de Pavert*

Aix-Marseille University, Centre National de la Recherche Scientifique (CNRS), National Institute for Health and Medical Research (INSERM), Centre d’Immunologie de Marseille-Luminy (CIML), Marseille, France

**Abstract**

Innate Lymphoid Cells (ILC) are involved in homeostasis and immunity. Their dynamic differentiation and characterization depend on their tissue of residency and is adapted to their role within these tissues. Lymphoid Tissue inducer (LTi) cells are an ILC member and essential for embryonic lymph node (LN) formation. LNs are formed at pre-defined and strategic positions throughout the body and how LTi cells are initially attracted towards these areas is under debate. Besides their role in LN formation, LTi-like and the closely related ILC type 3 (ILC3) cells have been observed within the embryonic gut. New studies have now shown more information on their origin and differentiation within the embryo. This review will evaluate the embryonic LTi cell origin from a specific embryonic hemogenic wave, which has recently been described in mouse. Moreover, I will discuss their differentiation and similarities with the closely related ILC3 cells in embryo and adult.

**Article Info**

Article history:
Received 25 September 2020
Accepted 9 December 2020
Available online 10 December 2020

Keywords:
ILC3
ILC
Hemogenic endothelium
Bone-marrow
Hematopoietic stem cells (HSC)
Lymph node

The enigmatic Innate Lymphoid Cell (ILC) family consists of 3 main family members in which transcription factors for development, marker expression and functionality are shared [1–3]. These are the 1) ILC1 and natural killer cell (NK), 2) ILC2 and 3) ILC3 and Lymphoid Tissue Inducer (LTi) cell members. Their role in defense and repair is versatile, as are their cues for differentiation in situ determining their action. NK cells are considered cytotoxic ILCs, while generally other ILCs are considered ILC-helper cells. The LTi cells were previously considered part of the ILC3 ontogeny, based on retinoic acid orphan receptor isoform γt (RORγt) expression plus overlap in marker and cytokine expression. However, in both human and mice, ILC3 progenitors cells require the transcription factor promyelocytic leukemia zinc finger (Plzf) (encoded by

* Corresponding author. Centre d’Immunologie de Marseille-Luminy (CIML), 163 avenue de Luminy | Case 906, 13288 Marseille cedex 9, France.
  E-mail address: vandepavert@ciml.univ-mrs.fr.
  Peer review under responsibility of Chang Gung University.
  https://doi.org/10.1016/j.bj.2020.12.003
  2319-4170 © 2020 Chang Gung University. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
gene Zinc finger and BTB domain containing 16 (Zbtb16) for differentiation [4,5], while in the mouse Zbtb16 knock-out LTi cells were still observed [6]. Therefore, LTi cells are now considered to be separate from ILC3 cells [7]. Additionally, evolutionarily the LTi cells emerged later when compared to the other ILCs, and their function in LN formation was mainly associated with placentation [8,9].

LTi cells are essential for the formation of the secondary lymphoid organs during embryogenesis. They interact with the Lymphoid Tissue organizer (LTo) cells at specific locations within the embryo to form first aggregates which are named LN anlagen. There is some discussion on which cells attract the first LTi cells involved in the initiation of LN formation when using different mouse models [10–12].

ILC3s, which consists of Natural cytotoxicity triggering receptor 1 (Nkp46)+ and Nkp46− (LTi-like) cells, have immune modulatory and homeostatic roles within the gut. LTi cells have a unique function during embryogenesis and are the first of the ILCs to be observed during embryogenesis [11]. In later embryonic stages other ILCs were reported, mainly in gut and lung [13–15], but their role during embryogenesis is unclear. ILCs were shown to be derived from the HSC lineage within the bone-marrow in adult [16–19]. However, since there is no contribution from bone-marrow within the mouse embryo, the embryonic ILCs, like embryonic LTi cells, are likely to be derived from another hematopoietic lineage than from the HSC derived lineage. During adulthood, these embryonic LTi cells are replaced by bone-marrow derived LTi cells. The role of replaced LTi cells in adult remains obscure.

In this review, I will discuss the role of the LTi cells within LN formation and evaluate the newest insights on initiation of LN formation. Furthermore, I will discuss the new developments in LTi cell ontology and functioning, also in relation to the closely related ILC3s.

### ILC ontogeny

**Hemogenic endothelium progenitors**

During early embryogenesis, few endothelial cells undergo Endothelial to Hematopoietic cell Transition (EHT) to become hematopoietic progenitor cells [20–22]. Small clusters of hematopoietic progenitors appear within the yolk-sac and embryo, from which cells bud off and are transported through the vascular system. Recent studies using single cell sequencing have contributed to the understanding of the earliest genes to facilitate EHT, such as CD44 and RUNX family transcription factor 1 (Runx1) [23–25]. The first wave of hematopoietic progenitors originates from the yolk-sac and occurs between embryonic gestation day 7.5 (E7.5) until around E9 in mouse. This wave includes progenitors for microglia, erythroid-myeloid progenitors, neutrophils, and mast cells [26–28]. Later lineages and progenitors for hematopoietic stem cell precursors (pre-HSCs) appear from embryonic arterial walls between E8.5-E11.5 [20,21].

The most studied embryonic hemogenic site in different organisms is the aorta-gonadal-mesonephros (AGM) [29], although other hemogenic endothelial sites to generate hematopoietic progenitors such as the vitelline artery, heart endocardium, head somitic region and umbilical cord were described in mouse [30–33]. Macrophages located in the heart-valves in mouse were shown to be derived from the heart endocardium [33]. However, it is not clear which other specific hematopoietic lineages appear from these embryonic sites.

In vitro cultured mouse yolk-sac cells isolated at E8.5 had a potential to become NK cells [15]. To directly show a relation between the yolk-sac and NK cells fate mapping models are required. Simic et al. [19] used the Cxcr4-CreERT2 fate mapping model to exclude a yolk-sac contribution as chemokine receptor Cxcr4 is not expressed within the yolk-sac [19,34,35]. Consequently, progenitors from the yolk-sac don’t express Cxcr4 [35]. Fate mapping in the Cxcr4-CreERT2 model only labelled embryonic derived progenitors [35] and it was shown that LTi cell progenitors originated around E8.5 from an embryonic hemogenic source [19]. Since the first hemogenic clusters in the AGM are observed after E8.5 [20,23], the LTi hemogenic source could either be the embryonic vitelline artery or the AGM [32]. Described as active in later stages, other embryonic regions were less likely to be the source for LTi cells [30,31,33]. The appearance of the embryonic LTi progenitors preceded the appearance of the pre-HSCs, making it unlikely that embryonic LTi cells are derived from HSCs. On the contrary, embryonic LTi cells involved in LN formation were replaced in the adult mice by bone-marrow HSC derived LTi cells, as was also shown for ILC2s and some ILC3s [14,36]. In human, ILCs were observed in the fetal gut but it has not been shown if they are HSC derived, nor if they will be replaced in the neonate by ILCs from HSCs in the bone-marrow [37]. Interestingly, thymic LTi cells in the mouse embryo around E18 were described to originate from HSC and could indicate the first LTi cells to originate from a HSC origin [38]. How the HSC derived ILCs functionally relate to the embryonic derived ILC they replace is not yet known.

**Fetal liver**

Hematopoietic progenitors migrate from the hemogenic endothelial sites towards the fetal liver (FL). Intriguingly, in mouse embryos the FL is mostly colonized around E11.5, so it is unclear where earliest hematopoietic progenitors reside between E7.5-E11. Within the FL, progenitors expand and differentiate toward precursors stages of their respective lineages, except for the microglial precursors which differentiate within the brain [39]. The FL plays an important role in the expansion of the progenitors as it was estimated that the progenitors multiply up to 33 times within this environment [40].

Common Lymphoid Progenitors (CLP) are present within the FL and express Fms related receptor tyrosine kinase 3 (Flt3) [7,19,41]. They are driven towards an ILC lineage by the expression of the Inhibitor of DNA binding 2 (Id2), which inhibits Single-stranded DNA-binding protein (E2A) functioning and thereby excludes commitment to a B-cell lineage [42]. At this stage, they are named αβ-Integrin expressing Lymphoid Precursor (αLP) cells. Flt3 RNA transcripts were not observed in this stage, and protein expression was detected on a αLP subset [7,19,43]. An αLP Flt3− subset is sensitive to Notch signaling and affects its proliferation [43] (please see the
review by Golub in this issue for the role of Notch in ILC differentiation). Within the αLP Flt3− stage, transcription factor Plzf marks differentiation into the ILC-Precursor (ILCP), which will generate ILC1, 2 and 3 cells in both human and mouse [4–6]. In adult mouse Plzf expression was reported to be lowered, while it remained high in human ILCs [4]. LTi-precursors (LTiP) in mouse, on the other hand, do not require Plzf, express chemokine receptors CXCR5 and CXCR6, and appear to segregate from the other ILC populations [6,7,44,45] (reviewed in Ref. [46]) [Fig. 1]. These chemokine receptors expressed during the LTiP stage could aid their migration to- and retention within the LN anlagen, essential for the next phase in LTi differentiation.

The role of mature ILC3 and LTi cells within the mouse FL is unclear. Several studies reported on the RORγt expressing (mature) ILC3 and LTi cells within the mouse FL [7,36,47]. On the other hand, the number of LTi0 and LTi4 cells within the FL was very low compared to LN anlagen enriched tissue [19,48]. Single cell sequencing of the FL and LN anlagen enriched tissue revealed that there was no direct connection in ontogeny between LTiP and LTi cells within the FL, while this was evident within the peripheral studied LTi cells [19]. Therefore, the final maturation would be most likely to occur within the LN anlagen, and in this scenario LTi cells present within the FL migrated back from the embryo.

ILC3s and LTi cells in LN anlagen and embryonic gut

αLP-LTIP cells migrate out from the FL towards the LN anlagen to differentiate into LTi0 and finally the mature LTi4 cells. During this transition, RORγt expression is induced by retinoic acid which leads to LTi lineage commitment. Lack of retinoic acid signaling within these cells halts LTi differentiation [49]. RORγt drives the transcriptional program for LTi cells in both human [50] and mice [51], although there have been RORγt deficient LTi cells observed [51,52]. However, these are not sufficient for continuation of LN formation, as Rorc (RORγt) knock-out mice are devoid of LN [51,53] and RORc deficient humans did not have palpable LNs [50]. Notch was shown to be involved in proliferation of the αLP population [45], but Notch signaling is not necessary for LTi commitment nor differentiation [46] (please see the review by Golub in this issue for the role of Notch in ILC differentiation). The LTi0 cells do not yet express the molecules necessary for interaction with mesenchymal cell within the lymph node anlagen niche [49,54]. Only after differentiation into the mature LTi4 stage, these cells interact and amplify the synthesis of cytokines and adhesion factors [Fig. 2]. This leads to the attraction and retention of more LTiP and LTi cells.

It is unclear whether there is only one LTi4 cell population. Mosaic CD11b and MHCII expressing LTi cells were observed within the embryo [48,51,55]. Using single cell sequencing of the LN anlagen enriched tissue, two separate LTi4 clusters were observed. The first LTi4 population expressed Il22, a cytokine involved in gut immunity. Also, Arg1 is expressed within this LTi4 population, which was also associated with fetal gut ILC precursors (fILCP) and ILC2s [13]. Specifically, in the same study, the fetal gut contained Arginase 1(Arg1)YFP+ LTi fate mapped cells and a smaller Arg1YFP− population [13], confirming two separate LTi4 populations also within the

![Fig. 1 Embryonic LTi cell ontogeny.](image-url)
The fILCPs could generate ILC1, 2 and 3 and were not fate mapped by the RORγt-Cre reporter, indicating that they are likely analogous to aLP and ILCP cells. Arg1 transcripts were not observed within fetal liver progenitors but only in the LN anlagen enriched tissue [19], indicating that Arg1 could be expressed after leaving the FL and entering peripheral LN anlagen or fetal gut. The second LTi4 population observed in the single cell sequencing study was segregated based on genes associated with Mayor histocompatibility complex II (MHCII), and hence named LTi4-II. Within the LTi4-II population, Cfp (Complement Factor Properdin) was observed, a ligand for binding to Nkp46 [56]. This could indicate that the LTi4-II population produce the ligand for Nkp46+ NK, ILC1, ILC3 cells, but this has not yet been shown within the adult. A relation between the two embryonic LTi populations in the LN anlagen and the Arg1+ or MHCII+ ILC3 and LTi-like cells observed in the gut remains to be established.

**Origin of ILCs and LTi cells in adult**

Hematopoietic lineages within the adult are almost all derived from HSC residing within the bone-marrow. Bone-marrow derived ILC precursors in the mouse do not express Arg1, while embryonic ILCPs express Arg1 [13]. This is an indication that the differentiation pathway towards embryonic derived ILCs is likely different than those derived from HSCs in the adult bone-marrow. The mouse embryonic LTi cells, ILC3s and ILC2s were shown to be replaced by bone-marrow HSC derived ILCs [14,19,36]. Also, it was shown that ILCs can be generated from the bone-marrow using elegant reporter mouse models and in vitro differentiation [13,16–18], although only 1 study reported the generation of LTi cells from bone marrow, while the other reporter mouse models could not follow LTi cells in their fate-mapping models [41]. The discrepancy between these studies can be explained by the differentiation stage that is used as source for the in vitro- or in vivo differentiation
primary lymphoid organs, like mesenteric and peripheral lymph nodes (LN) and Peyer’s patches, are formed during embryogenesis in which the LTi cells are critical. Consequently, deleting or mutation of RORc in both mice [51] and human [50] results in loss of LTi cells and concomitantly loss of LNs (reviewed in Refs. [11]). RORc deficient humans lacked palpable LNs but still had tonsils, but are surprisingly only more sensitive to lymphopenia vs. bone-marrow derived ILCs, and thus affect their functioning. More studies are required to understand the precise ILC progenitors and their differentiation pathways and what the functional difference is between the embryonic vs. adult ILCs.

### LTi cells in embryonic lymph node formation

Secondary lymphoid organs, like mesenteric and peripheral lymph nodes (LN) and Peyer’s patches, are formed during embryogenesis in which the LTi cells are critical. Consequently, deleting or mutation of RORc in both mice [51] and human [50] results in loss of LTi cells and concomitantly loss of LNs (reviewed in Refs. [11]). RORc deficient humans lacked palpable LNs but still had tonsils, but are surprisingly only more sensitive to Mycobacteria and Candida due to defective γδ-T cells and CD4⁺CCR6⁺CXCR3⁻αβ⁺ T-cells [50]. The presence of the tonsils, and other lymphoid structures like spleen which do not rely on LTi cells could be sufficient to drive the adaptive immune response. In mouse, initiation of most lymph nodes occurs between E12.5 until E15.5 [Figs. 2 and 3]. The aggregates of LTi- and mesenchymal cells, called lymph node anlagen, are present until birth in mouse. Final organization of the LN due to differentiation of the stromal subsets and attraction of the specific lymphocytes to their respective regions take place in the first weeks after birth. On the contrary, in human, LN organogenesis takes place around the 12–17th week of pregnancy and humans are born with a fully organized LN at birth [59].

The first event which can be visualized in embryonic LN formation is the aggregation of the LTi cells at fixed positions within the embryo [Fig. 2]. The chemokine CXCL13 is essential for the aggregation of the LTi cells in most LN anlagen, except for the mesenteric LN [60,61]. CXCR5⁺ LTiP cells are present within the LN anlagen, to be retained by local CXCL13 expression within the niches where LN are formed [7,19,43]. The role of CXCR6 [43,44] on these cells remains unknown in the attraction toward the LN niche. Only CCR7 was shown to be very potent in attracting LTi cells, but only when lymphatic endothelial cells secrete the ligand CCL21 [12,52,61]. In later LN formation stages, after lymphotoxin signaling and when the mesenchymal cells have differentiated into lymphoid tissue inducer (LTo) cells, the other CCR7 ligand CCL19 is expressed by LTo cells within the LN anlagen. This occurs around the time when the lymphatic endothelial cells have circumvented the LN anlagen. Some rescue could be observed by the lymphatic endothelial cell (LEC) expressed chemokine CCL21 [61], although these are likely to be aggregations within lymphatic vessels [12]. The presence of LECs and thus expression of CCL21 occurred after initial LTi cell aggregation and initial CXCL13 expression within the LN anlagen [12,52]. Moreover, lack of all lymphatic endothelial cells in the Prox1 knock-out mouse model did not affect the initial aggregation of the LTi cell clusters [62]. Initial Cxcl13 expression, but not other chemokines like Ccl21 and Ccl19, is induced by retinoic acid. Cxcl13 expression is required to attract the first precursor LTi cells towards the LN anlagen niche. It was proposed that nearby neurons synthesize the retinoic acid, thus inferring to a neuronal influence on LN formation [52]. However, it is unclear which type of neurons are involved in LN formation. After the initial LTi cell differentiation, Receptor activator of nuclear factor κ B Ligand (RANK-L), also known as TNFSF11A, either on LTi cells [54,63] or mesenchymal cells [64] activates RANK on LTi cells. RANK signaling induced expression of Lymphotoxin-αβ2 ligand on the LTi cells, which is the latest maturation step.
of the LTi cell. Thus, loss of this signaling resulted in the loss of LTi4 cells and consequently loss of lymph nodes \[54,64\]. Lymphotoxin-α,β will subsequently interact with its LTβ-receptor on the mesenchymal cells. This interaction triggers the expression of cytokines like IL7, chemokines like Cxcl13 and adhesion molecules like Madcam-1 \[63,65\], which attract and retain more (precursor) LTi cells. These increasing interactions results in an amplification of the process and hence a strong increase in the size of the aggregate.

There is currently a discussion on the definition of the initial phase of LN formation. It was suggested that embryonic lymphatic vessels interacted with LTi cells through lymphotxin signaling and that this delineated the initial event of LN formation \[10\]. Indeed, lymphatic vessels play an important role in lymph node formation but notably during the expansion phase. During the earliest clustering of LTi cells, well before E14.5, lymphatic vessels were not present nor required \[12,52,62\]. Starting at E14.5 in the anterior lymph node anlage and later in the posterior located anlagen, LECs circumvent the LN anlagen and connect the lymphatic vasculature to the LN anlagen. This allows the migration of LTi cells from the skin towards the LN anlagen \[12,62,66\]. Notably, an elegant study by the Petrova lab showed that flow from the lymphatic vasculature was important for Cxcl13 expression within the inguinal lymph node anlagen. Blocking lymghangiogenesis by administering vascular endothelial growth factor receptor 3 (VEGFR3)-blocking antibodies resulted in an arrest of the study by the Petrova lab showed that flow from the lymphatic vasculature towards the LN anlagen \[12,62,66\]. Starting at E14.5 in the anterior lymph node anlagen and later in the posterior located anlagen, LECs circumvent the LN anlagen and connect the lymphatic vasculature to the LN anlagen. This allows the migration of LTi cells from the skin towards the LN anlagen \[12,62,66\]. Notably, an elegant study by the Petrova lab showed that flow from the lymphatic vasculature was important for Cxcl13 expression within the inguinal lymph node anlagen. Blocking lymghangiogenesis by administering vascular endothelial growth factor receptor 3 (VEGFR3)-blocking antibodies resulted in an arrest of the small, initial, LTi cell aggregate and significant fewer LTi4 cells (VEGFR3)-blocking antibodies resulted in an arrest of the administering vascular endothelial growth factor receptor 3 (VEGFR3)-blocking antibodies resulted in an arrest of the

ILC3 and LTi-like in adult lymph nodes and gut

In the adult mouse, RORγt\(^{+}\)CCR6\(^{-}\)CD4\(^{-}\) LTi4 cells are mainly observed in lymph nodes and in gut. Lymph node are important for the functioning of the adaptive immune system, as they organize and facilitate the interaction between antigen presenting cells and the lymphocytes. The antigens are transported towards the lymph nodes by the afferent lymphatic vessels either unbound or bound to antigen presenting cells. The lymphatic vessels are connected to the lymphatic subcapsular sinus circumventing the lymph node. The antigen and cells are spread over the subcapsular sinus and migrate into the B-cell follicles or into the T-cell areas, depending on the antigen size or type of antigen presenting cell \[70–72\] (reviewed in Ref. \[73\]). Each immune reaction is taking place in a specialized region within the lymph node, thus compartmentalizing the immune response. These regions are meticulously organized and maintained by specialized stromal cells. Initially, only T-cell zone stromal cells (fibroblastic reticular cells) in the paracortex, B-cell stromal zone cells (follicular dendritic cells) and endothelial cells were described (reviewed in Ref. \[74\]). This was later amended by the marginal reticular cells (MRC), positioned in the paracortex, adjacent to the B-cell follicles and just below the subcapsular sinus \[75\]. However, the use of single cell sequencing has allowed the identification of nine stromal cell clusters within the lymph node \[76\], each with specific expression profiles and functions (reviewed in Ref. \[74\]). These stromal cells differentiate from mesenchymal precursor cells, or LTo cells, in the first weeks after birth in the mouse \[77–79\]. Although there are indications that lymphotoxin signaling, retinoic acid or microbiota mediate mesenchymal differentiation \[52,78,80\], the specific cues for differentiation towards a specific stromal cell subset are yet unclear \[81\].

Embryonic LTi cells, which are involved in embryonic LN formation, are replaced in the adult by LTi cells derived from the bone-marrow \[19,36\]. Thus, since their origin is different, the LTi cells in adult are likely to be functionally different compared to the embryonic LTi cells. Within the lymph node, LTi cells are found adjacent to the MRC without an apparent function. Since the MRCs were assumed being a precursor for other stromal cells during expansion of the lymph node during inflammation \[77\], the MRC-LTi cell communication might reflect the interaction between embryonic LTi cells with LTo cells occurring during embryonic lymph node formation. Besides the obvious role for LTi cells during embryonic lymph node formation, there is not much known on their role in the adult. There is phenotypically not much difference, although adult LTi cells endogenously express OX40 and CD30 ligands, involved in clonal expansion and memory of lymphocytes, while the fetal LTi cells need DR3 stimulation to express these ligands \[82\]. It was described that adult LTi cells were involved in the formation of tertiary lymphoid structures during cancer \[83\]. They have been described in the restoration of lymphoid tissues, as they were involved in spleen restoration after viral infection \[84\] and rescue of mucosal associated lymphoid tissue (MALT) in an Id2-knock out model \[85\].

A close related LTi cell subset within the ILC3 branch is the LTi-like population, present in high numbers within the adult gut mucosa. These cells are different than the closely related Nkp46\(^{+}\)CCR6\(^{-}\)RORγt\(^{-}\) ILC3 cells, which originate from Nkp46\(^{+}\)CCR6\(^{-}\) progenitors driven by T-Bet which upregulates IFN-γ and Nkp46 expression \[86,87\]. LTi-like cells are characterized as Nkp46\(^{+}\)CCR6\(^{-}\) (CD4\(^{+}\)) ILC3 cells, and found to be
involved in antigen presentation and immune modulation and secrete IL22 [88,89]. They are guided by CCR7 expression [90] and play an important role in interaction between follicular Th-cells and IgA producing B-cells [91]. An embryonic LTi cell subset (LTi4-II) expressed MHCII related genes [19], and it is interesting to establish whether there is a lineage and functional relationship between embryonic LTi-I and LTi-like cells in the adult gut.

There are numerous reports stating the importance of ILCs in the immune defense. They are involved in immune cells interactions to induce IgA production on B-cells [90,91]. They secrete IL17 and notably IL22 secretion upon IL23R activation, shown in mice and human and in different disease settings [88,92–94]. Besides their role in immune reactions, IL22 secreted by ILC3s was shown to be also important for maintenance of epithelial integrity. IL22 from ILC3/LTi-like cells induced the fucosyltransferase 2 (Fut2) expression in gut epithelial cells, which is required for fucosylation and resistance to Salmonella typhimurium infection [95]. There is discussion on the possible redundancy of NKp46+ ILCs in the gut-immune response. A Ncr1 (NKp46)- Cre model was used to delete ILC3 cells or specifically knock-out IL22 within NKp46+ ILC3s during gut infection. In these models, the NKp46+ ILC3 population was shown to be redundant during an infection with Citrobacter rodentium and ILC3 deletion only affected cecal homeostasis [87]. However, IL22 expression in the NKp46+ CCR6+ LTi-like cell population was not affected in these models [87] and it remains unclear whether this population could (partially) rescue the loss of IL22 from the NKp46+ ILC3 population. Indeed, it was shown that the ILC3 are partially redundant but play an essential role in T-cell deficient mice [96]. In another example of possible redundancy it was observed that in patients with severe combined immunodeficiency (SCID), the restoration of the hematopoietic compartment did not restore the ILC family without any obvious susceptibility to a disease [57]. Lastly, in human patients with a RORc loss of function mutation, lacking RORγt functionality and thus all ILC3 and LTi-like cells, were only more susceptible to Mycobacterium and Candida infections. This effect was attributed to defective γδ- and αβ- T-cells but not ILC3’s [90]. Therefore, it remains unclear what the unique roles of ILC3 and LTi-like cells are within the gut. Is there indeed redundancy, as was proposed before [57,87], or is there a rescue mechanism which arises during fetal development and neonatal stages? Better mouse models, in which specifically ILC3 and/or LTi like cells can be deleted by induction at a specific time point to prevent a rescue mechanism during development, are required to answer this question. Additionally, the use of a unique gene for each population, but not genes such as Ncr1 or Rorc as drivers, are required to establish the specific effect of a specific ILC cell during disease.

Neuropilin-1 (NRP-1) was found to be expressed by ILC3 and LTi cells in mouse and human and involved in the formation of ectopic lymphoid organs, especially in the lungs of smokers and COPD patients [97]. Recently, Neuropilin-1 was also associated as host factor for Sars-Cov2 entry and the virus was associated with NRP-1 positive cells within the nasal cavity [98,99]. If Sars-Cov2 specifically transfects ILC3 and LTi cells is still unknown. It will be important to establish whether during this infection LTi cells could mediate ectopic lymphoid formation in lungs, which possibly exacerbates the immune reaction.

In general, ILC differentiation in embryo and adult is very flexible in order to adapt to the niche they reside in. Also, ILCs can be derived from different progenitors [reviewed in Ref. [100,101]]. Therefore, marker expression for the ILC family members can vary and depend on their origin and differentiation program. This complicates the determination of the ILC members and induces discussion on their nomenclature. Especially for the characterization of enigmatic ILC1 subset this has been problematic [102] and based on CyTOF analysis it was even suggested that there is no specific human ILC1 population [103]. Other testimonies on ILC dynamicity are that the ILC3 cells within the gut could differentiate into ILC1 cells [87], fetal human intermediate-ILC1 were observed to become NK and ILC3s [37] progenitors in the gut differentiate to ILC2 cells which migrate to the lung [104] and play an important role in interaction between follicular Th-cells and IgA producing B-cells [91]. An embryonic LTi can be derived from different starting points and provide a partial marker expression for human ILCs [105]. The origin of the ILCs, being embryonic or adult, is important to understand their eventual functioning. Therefore, it remains of much interest to pinpoint the embryonic homogenic source of the ILCs and when they are replaced in the neonate by bone-marrow derived ILCs. This knowledge will aid our understanding of their miscellaneous roles in immunity and how to possibly dampen them in unwanted immunological reactions.

Conflicts of interest

The author declares no conflict of interest.

Acknowledgements

The group was supported by the FRM Amorçage de jeunes équipes (AJE20150633331), ANR ACHN (ANR-16-ACHN-0011), ANR PCR1 (ANR-17-CE13-0029-01) and institutional grants from Inserm, CNRS and Aix-Marseille University to the CIML. I would like to thank Ana Cumanio for the discussions on the hematopoietic progenitors, Lionel Spinelli and Julie Bavais for their help on the transcriptional data. I am grateful to Milesa Simic, Shuaiwei Wang and especially Rachel Golub for critically reading the manuscript.

References

[1] Eberl G, Di Santo JP, Vivier E. The brave new world of innate lymphoid cells. Nat Immunol 2015;16:1–5.
[2] Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 Years on. Cell 2018;174:1054–66.
[3] Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells–a proposal for uniform nomenclature. Nat Rev Immunol 2013;13:145–9.

[4] Nagasawa M, Germar K, Blom B, Spits H. Human CD56+ innate lymphoid cells are functionally immature and their development from CD34+ progenitor cells is regulated by Id2. Front Immunol 2017;8:1047.

[5] Constantinides MG, Gudjonson H, McDonald BD, Ishizuka IE, Verhoef PA, Dinner AR, et al. PLZF expression maps the early stages of ILC1 lineage development. Proc Natl Acad Sci U S A 2015;112:5123–8.

[6] Constantinides MG, McDonald BD, Verhoef PA, Bendelac A. A committed precursor to innate lymphoid cells. Nature 2014;508:397–401.

[7] Ishizuka IE, Chea S, Gudjonson H, Constantinides MG, Dinner AR, Bendelac A, et al. Single-cell analysis defines the divergence between the innate lymphoid cell lineage and lymphoid tissue-inducer cell lineage. Nat Immunol 2016;17:269–76.

[8] Vivier E, van de Pavert SA, Cooper MD, Belz GT. The evolution of innate lymphoid cells. Nat Immunol 2016;17:790–4.

[9] Lane PJL, Gaspal FM, McConnell FM, Withers DR, Lane PF, Vivier E, et al. Multiple roles of lymphatic vessels in peripheral lymph node development. J Exp Med 2018;215:2760–77.

[10] Bando JK, Liang HE, Locksley RM. Identification and distribution of developing innate lymphoid cells in the fetal mouse intestine. Nat Immunol 2014;15:135–60.

[11] van de Pavert SA, Mebius RE. New insights into the evolution of CD4 immunity and tolerance? Front Immunol 2012;3:24.

[12] Onder L, Morbe U, Pikor N, Novkovic M, Cheng HW, HehlGans T, et al. Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity 2017;47:80–92. e4.

[13] van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. Nat Rev Immunol 2010;10:664–74.

[14] Bovay E, Sabine A, Prat-Luri B, Kim S, Son K, Willrodt AH, et al. Multiple roles of lymphatic vessels in peripheral lymph node development. J Exp Med 2018;215:2760–77.

[15] Lane PJL, Gaspal FM, Connell FM, Withers DR, Anderson G. Lymphoid tissue inducer cells: pivotal cells in mammalian development. Dev Cell 2020;53:229–40.

[16] Schneider C, Lee J, Koga S, Ricardo-Gonzalez RR, Neussbaum JC, Smith LK, et al. Tissue-resident group 2 innate lymphoid cells differentiate by layered ontology and in situ perinatal priming. Immunity 2019;50:1425–38. e5.

[17] Dege C, Fegan KH, Creamer JP, Berrien-Elliott MM, Luff SA, Kim D, et al. Potently cytotoxic natural killer cells initially emerge from erythroid-myeloid progenitors during mammalian development. Dev Cell 2020;53:229–39. e7.

[18] Xie W, Cherrier DE, Shea S, Vosshenrich C, Sarafini N, Petit M, et al. An Id2RFP-reporter mouse redefines innate lymphoid cell precursor potentials. Immunity 2019;50:1054–68. e3.

[19] Walker JA, Clark PA, Crisp A, Barlow JL, Szeto A, Ferreira ACF, et al. Polychromic reporter mice reveal unappreciated innate lymphoid cell progenitor heterogeneity and elusive ILC3 progenitors in bone marrow. Immunity 2019;51:104–18. e7.

[20] Seilliet C, Mielke LA, Amann-Zalcenstein DB, Su S, Gao J, Almeida FF, et al. Deciphering the innate lymphoid cell transcriptional program. Cell Rep 2016;17:435–47.

[21] Simic M, Manosalva I, Spilione L, Gentek R, Shayan RR, Siret C, et al. Distinct waves from the hemogenic endothelium give rise to layered lymphoid tissue inducer cell ontogeny. Cell Rep 2020;32:10804–16.

[22] Boisset J-C, Van Cappellen W, Andrieu-Soler C, Galjart N, Dziersak E, Robin C. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature 2010;464:116–20.

[23] Lancerin C, Sroczyńska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 2009;457:892–9.

[24] Golub R, Cumano A. Embryonic hematopoiesis. Blood Cells Mol Dis 2013;51:226–31.

[25] Baron CS, Kester L, Klaus A, Boisset JC, Thombyrajah R, Yvernoegau L, et al. Single-cell transcriptomics reveal the dynamic of haematopoietic stem cell production in the aorta. Nat Commun 2018;9:2517.

[26] Lis R, Karrasch CC, Polesou MG, Kumar B, Redmond D, Duran JGB, et al. Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature 2017;545:439–45.

[27] Zhu Q, Gao P, Tober J, Bennett L, Chen C, Uzun Y, et al. Developmental trajectory of pre-hematopoietic stem cell formation from endothelium. Blood 2020;136:845–56.

[28] McGrath KE, Frame JM, Fegan KH, Bowen JR, Conway SJ, Catherman SC, et al. Distinct sources of hematopoietic progenitors emerge before HSCs and provide functional blood cells in the mammalian embryo. Cell Rep 2015;11:1892–904.

[29] Mass E, Ballesteros I, Farlik M, Halbritter F, Günther P, Crozet L, et al. Specification of tissue-resident macrophages during organogenesis. Science 2016;353:aaf4238.

[30] Gentek R, Ghigo C, Hoefel G, Bulle MJ, Msallam R, Gautier G, et al. Hemogenic endothelial fate mapping reveals dual developmental origin of mast cells. Immunity 2018;48:1160–71. e5.

[31] Yvernoegau L, Klaus A, Maas J, Morin-Poulard I, Wejts B, Schulte-Merker S, et al. Multispecies RNA tomography reveals regulators of hematopoietic stem cell birth in the embryonic aorta. Blood 2020;136:831–44.

[32] Zovein AC, Turlo KA, Ponec RM, Lynch MR, Chen KC, Hofmann JJ, et al. Vascular remodeling of the vitelline artery initiates emergence of hematopoietic clusters. Blood 2010;116:3435–44.

[33] Shigeta A, Huang V, Zuo J, Zhou B, Shigeta A, Huang V, et al. Endocardially derived macrophages are essential for valvular remodeling article endocardially derived macrophages are essential for valvular remodeling. Dev Cell 2019;48:1–14.

[34] McGrath KE, Koniski AD, Malby KM, McGann JK, Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 1999;213:442–56.

[35] Werner Y, Mass E, Ballesteros I, Farlik M, Halbritter F, Gunther P, Ashok Kumar P, Ulas T, Hofmann JJ, et al. Endocardially derived macrophages are essential for valvular remodeling article endocardially derived macrophages are essential for valvular remodeling. Dev Cell 2019;48:1–14.

[36] Zovein AC, Turlo KA, Ponec RM, Lynch MR, Chen KC, Hofmann JJ, et al. Vascular remodeling of the vitelline artery initiates emergence of hematopoietic clusters. Blood 2010;116:3435–44.

[37] Shigeta A, Huang V, Zuo J, Zhou B, Shigeta A, Huang V, et al. Endocardially derived macrophages are essential for valvular remodeling article endocardially derived macrophages are essential for valvular remodeling. Dev Cell 2019;48:1–14.

[38] Zovein AC, Turlo KA, Ponec RM, Lynch MR, Chen KC, Hofmann JJ, et al. Vascular remodeling of the vitelline artery initiates emergence of hematopoietic clusters. Blood 2010;116:3435–44.

[39] Shigeta A, Huang V, Zuo J, Zhou B, Shigeta A, Huang V, et al. Endocardially derived macrophages are essential for valvular remodeling article endocardially derived macrophages are essential for valvular remodeling. Dev Cell 2019;48:1–14.
microenvironment in a time-dependent manner. Blood 2021;137:1024–36.

[39] Hoeffel G, Chen J, Lavín Y, Low D, Almeida FF, See P, et al. C-Myb+ erythroid-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 2015;42:665–78.

[40] Ema H, Nakauchi H. Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. Blood 2000;95:2284–8.

[41] Klose CSN, Flach M, Mohle I, Rogell L, Hoyler T, Ebert K, et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 2014;157:340–56.

[42] Boos MD, Yokota Y, Eberl G, Kee BL. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med 2007;204:1119–30.

[43] Chea S, Schmutz S, Burel-Defranoû X, et al. Single-cell gene expression analyses reveal heterogeneous responsiveness of fetal innate lymphoid progenitors to Notch signaling. Cell Rep 2016;14:500–10.

[44] Possot C, Schmutz S, Chea S, Boucontet L, Louise A, Cumano A, et al. Notch signaling is necessary for adult, but not fetal, development of RORγt+ innate lymphoid cells. Nat Immunol 2011;12:949–58.

[45] Schmutz S, Perchet T, Petit M, Banchi EG, et al. Notch signaling in group 3 innate lymphoid cells modulates their plasticity. Sci Signal 2016;9:ra45.

[46] Ishizuka IE, Constantines MG, Gadj lionson H, Bendelac A. The innate lymphoid cell precursor. Annu Rev Immunol 2016;34:299–316.

[47] Cherrier M, Sawa S, Eberl G. Notch, Id2, and RORγt sequentially orchestrate the fetal development of lymphoid tissue inducer cells. J Exp Med 2012;209:729–40.

[48] Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3- LTβ+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 1997;7:493–504.

[49] van de Pavert SA, Ferreira M, Domingues RG, Ribeiro H, Molenaar R, Moreira-Santos L, et al. Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity. Nature 2014;508:123–7.

[50] Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Williams A, Natarajan D, et al. Tyrosine kinase receptor RET is a key regulator of Peyer’s patch organogenesis. Nature 2007;446:547–51.

[51] Eberl G, Marmon S, Sunshine MJ, Rennert PD, Roses J, et al. Differential roles of LTβR signaling in group 3 innate lymphoid cells. J Exp Med 2007;204:1119–30.

[52] van de Pavert SA, Olivier BJ, Govers F, Vandenbossche MF, Greuter M, Verbeuren TJ, et al. Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat Immunol 2009;10:1193–9.

[53] Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Fiers W, Brenner-Morton S, et al. Requirement for RORγt in thymocyte survival and lymphoid organ development. Science 2000;288:2369–73.

[54] Kim D, Mebius RE, MacMicking JD, Jung S, Cupedo T, Testelin Y, et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 2000;192:1467–78.

[55] Mebius RE, Stüppner PR, Michie S, Butcher EC, Weissman IL. A developmental switch in lymphocyte homing receptor and endothelial vascular addressin expression regulates lymphocyte homing and permits CD4+ CD3- cells to colonize lymph nodes. Proc Natl Acad Sci U S A 1996;93:11019–24.

[56] Narni-Mancinelli E, Gauthier L, Baratin M, Guia S, Fenis A, Dehm ane AE, et al. Complement factor P is a ligand for the natural killer cell-activating receptor NKp46. Sci Immunol 2017;2:eamn9628.

[57] Vely F, Barlogis V, Vallentin B, Neven B, Piperegouli C, Ebbe M, et al. Evidence of innate lymphoid cell redundancy in humans. Nat Immunol 2016;17:1291–9.

[58] Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell 2017;168:1086–100. e10.

[59] Hoorweg K, Cupedo T. Development of human lymph nodes and Peyer’s patches. Semin Immunol 2008;20:164–70.

[60] Ansel KM, Ngo VN, Hyman PL, Luther SA, Förster R, Sedgwick JD, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000;406:309–14.

[61] Luther S a, Ansel KM, Cyster JG. Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J Exp Med 2003;197:1191–8.

[62] Vandenbossche MF, van de Pavert SA, Dillard ME, Greuter M, Covare S, Oliver G, et al. Lymph sacs are not required for the initiation of lymph node formation. Development 2009;136:29–34.

[63] Yoshida H, Naito A, Inoue JI, Satoh M, Santee-Coo per SM, Ware CF, et al. Different cytokines induce surface lymphotaxon-αβ on IL-7 receptor-α cells that differentially engender lymph nodes and Peyer’s patches. Immunity 2002;17:283–33.

[64] Sugiyama M, Nakato K, Jinnohara T, Akiba H, Okumura K, Ohno H, et al. Expression pattern changes and function of RANKL during mouse lymph node microarchitecture development. Int Immunol 2012;24:369–78.

[65] Vandenbossche MF, Greuter M, Gouwast D, Dewint P, Ware CF, et al. LTβR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen. J Immunol 2009;182:5439–45.

[66] Wang Z, Chai Q, Zhu M. Differential roles of LTβR in endothelial cell subsets for lymph node organogenesis and maturation. J Immunol 2018;201:69–76.

[67] Cupedo T. Human lymph node development: an inflammatory interaction. Immunol Lett 2011;138:4–6.

[68] Veiga-Fernandes H, Coles MC, Foster KE, Patel A, Williams A, Natarajan D, et al. The inflammatory interaction. Immunol Lett 2011;138:4–6.

[69] Martens R, Permanyer M, Werth K, Yu K, Braun A, Halle S, Hoffmann K, et al. Efficient homing of T cells via afferent lymphatics engenders switching of low-molecular-weight antigen to lymph node follicles. Immunity 2009;30:264–76.

[70] Braun A, Worbs T, Moschovakis GL, Halle S, Hoffmann K, Boelter J, et al. Afferent lymph–derived T cells and DCs use different chemokine receptor CCR7–dependent routes for entry into the lymph node and intranodal migration. Nat Immunol 2011;12:879–87.

[71] Martens R, Permanyer M, Werth K, Yu K, Braun A, Halle S, et al. Efficient homing of T cells via afferent lymphatics requires mechanical arrest and integrin-supported chemokine guidance. Nat Commun 2020;11:1114.

[72] Tarkkanen S, Salminen M. Lymphatic endothelial cells of the lymph node. Nat Rev Immunol 2020;20:566–78.

[73] Gentek R, Bajénoff M. Lymph node stroma dynamics and approaches for their visualization. Trends Immunol 2017;38:236–47.
